PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that the following clinical and preclinical abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as well as for anti-PD-1 and anti-CD70 antibody candidates for cancer treatment, are expected to be the subject of presentations at the Annual Meeting of the American Society of Clinical Oncology, being held May 30-June 3, 2008 in Chicago:
Clinical and Preclinical Data of Additional Immunotherapy and Antibody-Drug Conjugate Programs
More information about the ASCO Annual Meeting may be found at www.asco.org.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, x2216, or
Nichol Harber, Corporate Communications (media), +1-609-430-2880, x2214,
both for Medarex, Inc.
Web site: http://www.medarex.com/
http://www.asco.org/
Company News On-Call: http://www.prnewswire.com/comp/108265.html /
